Last Week in Longevity #11 - $1B raised across 11 deals
Your weekly business digest of everything that happened in longevity.
👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.
💸 Closed funding rounds
US$ 1,065M raised across 11 deals (↗️ +18% vs. US$ 899M across 6 deals last week)
Direct Longevity Interventions (Category 1)
NewLimit – US$ 45M (strategic extension) | San Francisco, USA
What they do: Develop epigenetic reprogramming therapies to return aged cells to more youthful states and restore organ function (company highlights liver as a target tissue).
Why it matters: Reprogramming is mechanistically upstream of age-related diseases; successful restoration of youthful gene-expression programs could extend healthspan independent of a single disease label. Their recent communications emphasise plans toward clinical translation in liver, a tractable first indication to demonstrate rejuvenation in humans.
Investors: New round features Lilly Ventures, Duke University, Section 32 (S32), among others.
Valuation: $1.62B
Simple Life – US$ 35 M (Series A) | San Francisco, USA
What they do: AI-powered behaviour-change platform combining nutritional coaching, metabolic tracking & community engagement for sustainable weight loss.
Why it matters: Metabolic dysfunction is an upstream driver of ageing. Precision lifestyle modification remains one of the most validated longevity levers.
Investors: Accel (lead), Index Ventures, Samsung Next, Greycroft and others.
Valuation: Unknown
WellTheory – US$ 14 M (Series A) | New York, USA
What they do: Virtual care platform for autoimmune management through personalised nutrition and lifestyle medicine.
Why it matters: Targets chronic inflammation — a key biological hallmark of ageing — via structured prevention and clinically guided habit change.
Investors: General Catalyst (lead), Accretive, Lux Capital.
Valuation: Unknown
Longevity-Aligned Disease Modification (Category 2)
Liberate Bio – US$ 31 M (Seed) | Cambridge, USA
What they do: In vivo genetic medicines reprogram immune cells using mRNA & LNPs to treat autoimmunity and cancer.
Why it matters: Rejuvenates immune resilience by correcting dysfunction at a root cause of ageing.
Investors: Khosla Ventures.
Valuation: Unknown
Pelage Pharmaceuticals – US$ 120 M (Series B) | Los Angeles, USA
What they do: Reactivates dormant hair-follicle stem cells to reverse hair loss.
Why it matters: Demonstrates functional stem-cell rejuvenation — a central anti-ageing mechanism.
Investors: ARCH Venture Partners, GV, Visionary Ventures, Main Street Advisors, YK Bioventures.
Valuation: Unknown
Kardigan – US$ 254 M (Series B) | San Francisco & Princeton, USA
What they do: Late-stage portfolio of personalised cardiovascular medicines targeting root causes of heart disease.
Why it matters: Cardiovascular repair directly extends lifespan and healthspan by slowing vascular ageing.
Investors: Fidelity Management, T. Rowe Price, ARCH Venture Partners, Sequoia Heritage.
Valuation: Unknown
Adcytherix – €105 M (≈ US$ 114 M, Series B) | Marseille, France
What they do: Develops novel antibody-drug conjugates (ADCs) for solid tumours with reduced toxicity.
Why it matters: Safer, more precise cancer therapeutics enhance survivorship and life expectancy.
Investors: Bpifrance, Sofinnova Partners, Andera Partners, Kurma Partners.
Valuation: Unknown
Nova Pulse Therapeutics – Undisclosed (Series A) | New York, USA
What they do: Uses focused ultrasound to destroy tumours and stimulate immune response.
Why it matters: Offers a non-toxic, regenerative oncology approach — a major step toward longevity-compatible cancer care.
Investors: Founders Fund (Peter Thiel), Bezos Expeditions, ARCH Venture Partners.
Valuation: Unknown
Tubulis – US$ 335 M, Series C | Munich, Germany
What they do: Next-gen ADC platform with proprietary linker chemistry for more precise, less toxic cancer drugs.
Why it matters: Improves efficacy and safety in oncology—boosting healthy longevity through durable, low-toxicity remission.
Investors: EQT Life Sciences, Andera Partners, Mubadala Capital, Fund+, BioMedPartners, Roche Venture Fund.
Valuation: Unknown
Longevity Enablers (Category 3)
CoMind – US$ 102.5 M (Series B) | London, UK
What they do: Non-invasive AI platform for continuous brain-activity and blood-flow monitoring.
Why it matters: Enables early detection of cognitive decline and neurodegeneration—shifting brain health from reactive care to prevention.
Investors: Andreessen Horowitz, General Catalyst, Mubadala Capital, others.
Valuation: Unknown
Adaptyx Biosciences – US$ 14 M (Seed) | Menlo Park, USA
What they do: Multi-analyte biowearable for continuous molecular monitoring using AI analytics.
Why it matters: Real-time detection of metabolic drift and inflammation allows truly preventive medicine.
Investors: Interlagos Ventures (lead), Overwater Ventures, Starbloom Capital, CZ Biohub, Cantos Ventures, and others.
Valuation: Unknown
📰 Top longevity business news
The CEO of General Catalyst says that longevity care should be reimbursable
What happened:
Hemant Taneja, CEO of the venture firm General Catalyst, in a podcast, argued that longevity and personal health interventions should be reimbursed by health-insurers, rather than treated as premium wellness add-ons. Read more here.Why it matters:
Of course, I agree! This would mark an important strategic shift in how longevity could integrate into mainstream healthcare economics. If reimbursement frameworks evolve to value healthspan extension alongside disease treatment, the longevity market could grow far beyond wealthy consumers, tapping insurer budgets and institutional payers. But realising this will require proof of ROI and policy alignment, making clinical validation and outcomes data the next competitive frontier for longevity companies.
🗓 Events & meetups (Europe-only)
(LU) Longevity & Biohacking Retreat (Oct-Nov 24-04, 2025)
(CH) Global Longevity Summit (Oct 28-30, 2025)
(FR) Tech for Longevity 2025 (Nov 25-26, 2025)
(ES) 4th Longevity World Forum (Feb 18-20, 2026)
(CH) SIP Longevity Retreat (Apr 20-24, 2026)
(PT) 4th Global Longevity Med Summit (May 6-7, 2026)
(DE) LIFE Summit (May 29-30, 2026)
(IE) Longevity Summit Dublin (Jun 24-26, 2026)
(NL) HLTH Europe (Jun 15-18, 2026)
(CZ) 8th World Aging & Rejuvenation Conference (Jun 18-19, 2026)
(UK) The Longevity Show (Jun 26-27, 2026)
(AT) 2nd World Congress on Future of Aging & Rejuvenation Science (Jul 20-21, 2026)
(DE) POLLY Longevity Festival (Aug 21-23, 2026)
💼 New Longevity jobs (Europe-only)
(Berlin) Co-Founder @ Allseven Healthspan
(Hamburg) Praxismanager/in @ Privatpraxis Longevity Jorge Castaneda M.D.
👉 To see the full list of all Longevity jobs, visit our Job Board.
Keep building the future of longevity - one week at a time.
Fabian
P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.